TNF receptor 2 pathway: drug target for autoimmune diseases

Although drug development has advanced for autoimmune diseases, many current therapies are hampered by adverse effects and the frequent destruction or inactivation of healthy cells in addition to pathological cells. Targeted autoimmune therapies capable of eradicating the rare autoreactive immune cells that are responsible for the attack on the body's own cells are yet to be identified. This Review presents a new emerging approach aimed at selectively destroying autoreactive immune cells by specific activation of tumour necrosis factor receptor 2 (TNFR2), which is found on autoreactive and normal T lymphocytes, with the potential of avoiding or reducing the toxicity observed with existing therapies.

[1]  D. Harlan,et al.  A Single Course of Anti-CD3 Monoclonal Antibody hOKT3γ1(Ala-Ala) Results in Improvement in C-Peptide Responses and Clinical Parameters for at Least 2 Years after Onset of Type 1 Diabetes , 2005, Diabetes.

[2]  E. Unanue,et al.  Immunological Reversal of Autoimmune Diabetes Without Hematopoietic Replacement of ß Cells , 2006, Science.

[3]  B. Millward,et al.  NFκB Polymorphisms and susceptibility to type 1 diabetes , 2001, Genes and Immunity.

[4]  R N Maini,et al.  Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. , 2000, The New England journal of medicine.

[5]  Y. Yoshioka,et al.  Structure-function relationship of tumor necrosis factor (TNF) and its receptor interaction based on 3D structural analysis of a fully active TNFR1-selective TNF mutant. , 2009, Journal of molecular biology.

[6]  A. Cope,et al.  Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases. , 1992, Arthritis and rheumatism.

[7]  P. Emery,et al.  Anti-tumor necrosis factor-alpha therapy-induced vasculitis: case series. , 2003, The Journal of rheumatology.

[8]  R. Beyaert,et al.  Function and regulation of tumor necrosis factor receptor type 2. , 2004, Current medicinal chemistry.

[9]  N. Maclaren,et al.  Association of LMP2 and LMP7 genes within the major histocompatibility complex with insulin-dependent diabetes mellitus: population and family studies. , 1995, American journal of human genetics.

[10]  D. Goeddel,et al.  Monoclonal antibodies specific for murine p55 and p75 tumor necrosis factor receptors: identification of a novel in vivo role for p75 , 1995, The Journal of experimental medicine.

[11]  Takuma Hayashi,et al.  Reply to 'LMP2 expression and proteasome activity in NOD mice' , 2000, Nature Medicine.

[12]  R. Brink,et al.  Tumor Necrosis Factor Receptor 2 (TNFR2) Signaling Is Negatively Regulated by a Novel, Carboxyl-terminal TNFR-associated Factor 2 (TRAF2)-binding Site* , 2005, Journal of Biological Chemistry.

[13]  Tumor necrosis factor-α is toxic via receptor 1 and protective via receptor 2 in a murine model of myocardial infarction , 2007 .

[14]  A. Kuznetsov,et al.  Reversal of Diabetes in Non-Obese Diabetic Mice Without Spleen Cell-Derived ß Cell Regeneration , 2006, Science.

[15]  É. Mezey,et al.  Reversal of Sjögren’s-like syndrome in non-obese diabetic mice , 2006, Annals of the rheumatic diseases.

[16]  U. Hieber,et al.  Tumor necrosis factor for the treatment of malignancies. , 1994, Oncology.

[17]  Y. Fu,et al.  Abnormal class I assembly and peptide presentation in the nonobese diabetic mouse. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[18]  G. Kollias,et al.  Tumor necrosis factor‐receptor 2 is up‐regulated on lamina propria T cells in Crohn's disease and promotes experimental colitis in vivo , 2002, European journal of immunology.

[19]  Javier Martín,et al.  Study of functional variants of the BANK1 gene in rheumatoid arthritis. , 2009, Arthritis and rheumatism.

[20]  R. Flavell,et al.  A Dual Role for TNF-α in Type 1 Diabetes: Islet-Specific Expression Abrogates the Ongoing Autoimmune Process When Induced Late but Not Early During Pathogenesis1 , 2001, The Journal of Immunology.

[21]  P. V. van Riel,et al.  Development of type 1 diabetes in a patient treated with anti-TNF-α therapy for active rheumatoid arthritis , 2009, Diabetologia.

[22]  K. Schlett,et al.  Tumor Necrosis Factor (TNF)-mediated Neuroprotection against Glutamate-induced Excitotoxicity Is Enhanced by N-Methyl-D-aspartate Receptor Activation , 2004, Journal of Biological Chemistry.

[23]  A. Silman,et al.  Association between rheumatoid arthritis and polymorphism of tumor necrosis factor receptor II, but not tumor necrosis factor receptor I, in Caucasians. , 2001, Arthritis and rheumatism.

[24]  S. Pervaiz,et al.  TNF receptor superfamily‐induced cell death: redox‐dependent execution , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[25]  S. Mohand-Said,et al.  Neurodegenerative and Neuroprotective Effects of Tumor Necrosis Factor (TNF) in Retinal Ischemia: Opposite Roles of TNF Receptor 1 and TNF Receptor 2 , 2002, The Journal of Neuroscience.

[26]  M. Kubeš,et al.  TNF signaling: early events and phosphorylation. , 2007, General physiology and biophysics.

[27]  L. Kuller,et al.  The Pittsburgh Insulin-dependent Diabetes Mellitus (IDDM) Morbidity and Mortality Study: Mortality Results , 1984, Diabetes.

[28]  V. Werth,et al.  Leukocytoclastic vasculitis due to etanercept. , 2000, The Journal of rheumatology.

[29]  Li-BoChen,et al.  Differentiation of rat marrow mesenchymal stem cells into pancreatic islet beta-cells , 2004 .

[30]  T. Vischer,et al.  Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity. , 1997, The Journal of rheumatology.

[31]  D. Furst,et al.  Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. , 1999, Annals of internal medicine.

[32]  C. Ware,et al.  Tumor necrosis factor (TNF) receptor expression in T lymphocytes. Differential regulation of the type I TNF receptor during activation of resting and effector T cells. , 1991, Journal of immunology.

[33]  D. Furst,et al.  Etanercept Therapy in Rheumatoid Arthritis , 1999, Annals of Internal Medicine.

[34]  D. Faustman,et al.  Selective death of autoreactive T cells in human diabetes by TNF or TNF receptor 2 agonism , 2008, Proceedings of the National Academy of Sciences.

[35]  D. Banner,et al.  Human tumor necrosis factor alpha (TNF alpha) mutants with exclusive specificity for the 55-kDa or 75-kDa TNF receptors. , 1993, The Journal of biological chemistry.

[36]  R. Gentz,et al.  Both tumor necrosis factor receptor types mediate proliferative signals in human mononuclear cell activation. , 1992, Journal of immunology.

[37]  M. Matsumoto,et al.  Analysis of the roles of CD4+ and CD8+ T cells in autoimmune diabetes of NOD mice using transfer to NOD athymic nude mice , 1992, European journal of immunology.

[38]  P. Rosenstiel,et al.  The Met-196 → Arg Variation of Human Tumor Necrosis Factor Receptor 2 (TNFR2) Affects TNF-α-induced Apoptosis by Impaired NF-κB Signaling and Target Gene Expression* , 2005, Journal of Biological Chemistry.

[39]  Takuma Hayashi,et al.  Essential Role of Human Leukocyte Antigen-encoded Proteasome Subunits in NF-κB Activation and Prevention of Tumor Necrosis Factor-α-induced Apoptosis* , 2000, The Journal of Biological Chemistry.

[40]  E. Leiter,et al.  Adoptive Transfer of Diabetes Into Immunodeficient NOD-scid/scid Mice: Relative Contributions of CD4+ and CD8+ T-Cells From Diabetic Versus Prediabetic NOD.NON-Thy-1a Donors , 1993, Diabetes.

[41]  J. Tschopp,et al.  Induction of TNF Receptor I-Mediated Apoptosis via Two Sequential Signaling Complexes , 2003, Cell.

[42]  M. Croft.  The role of TNF superfamily members in T-cell function and diseases , 2009, Nature Reviews Immunology.

[43]  P. V. van Riel,et al.  Dermatological conditions during TNF-α-blocking therapy in patients with rheumatoid arthritis: a prospective study , 2005, Arthritis research & therapy.

[44]  P. Scheurich,et al.  Enhancement of TNF receptor p60-mediated cytotoxicity by TNF receptor p80: requirement of the TNF receptor-associated factor-2 binding site. , 1997, Journal of immunology.

[45]  M. Feldmann,et al.  Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. , 2000, Arthritis and rheumatism.

[46]  D. Goeddel,et al.  TRAF2-mediated activation of NF-kappa B by TNF receptor 2 and CD40 , 1995, Science.

[47]  J. Drijfhout,et al.  Autoreactive CD8 T cells associated with beta cell destruction in type 1 diabetes. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[48]  D. Wagener,et al.  The Pittsburgh Insulin-dependent Diabetes Mellitus (IDDM) Morbidity and Mortality Study: Case-Control Analyses of Risk Factors for Mortality , 1985, Diabetes Care.

[49]  D. Schoenfeld,et al.  Reversal of established autoimmune diabetes by restoration of endogenous beta cell function. , 2001, The Journal of clinical investigation.

[50]  B. Aggarwal.  Signalling pathways of the TNF superfamily: a double-edged sword , 2003, Nature Reviews Immunology.

[51]  K Suzuki,et al.  TNF alpha promotes proliferation of oligodendrocyte progenitors and remyelination. , 2001, Nature neuroscience.

[52]  M. Tansey,et al.  Journal of Neuroinflammation BioMed Central Review , 2008 .

[53]  P. Secchiero,et al.  Tumour necrosis factor‐related apoptosis‐inducing ligand sequentially activates pro‐survival and pro‐apoptotic pathways in SK‐N‐MC neuronal cells , 2003, Journal of neurochemistry.

[54]  D. Mann,et al.  Tissue expression and immunolocalization of tumor necrosis factor-alpha in postinfarction dysfunctional myocardium. , 1999, Circulation.

[55]  M. Sadelain,et al.  Prevention of diabetes in the BB rat by early immunotherapy using Freund's adjuvant. , 1990, Journal of autoimmunity.

[56]  Takuma Hayashi,et al.  NOD Mice Are Defective in Proteasome Production and Activation of NF-κB , 1999, Molecular and Cellular Biology.

[57]  J. Stockman.  Insulin Needs After CD3-Antibody Therapy in New-Onset Type 1 Diabetes , 2007 .

[58]  G. Galbraith,et al.  TRAF1-C5 as a Risk Locus for Rheumatoid Arthritis—A Genomewide Study , 2008 .

[59]  M. Dorf,et al.  PKC phosphorylation of TRAF2 mediates IKKalpha/beta recruitment and K63-linked polyubiquitination. , 2009, Molecular cell.

[60]  M. Karin,et al.  NOD2 and Crohn's disease: loss or gain of function? , 2005, Immunity.

[61]  D. Huscher,et al.  New onset or exacerbation of psoriatic skin lesions in patients with definite rheumatoid arthritis receiving tumour necrosis factor α antagonists , 2005, Annals of the rheumatic diseases.

[62]  Judy H. Cho,et al.  Functional annotation of a novel NFKB1 promoter polymorphism that increases risk for ulcerative colitis. , 2004, Human molecular genetics.

[63]  P. Scheurich,et al.  Tumor necrosis factor (TNF) receptor type 2 mediates thymocyte proliferation independently of TNF receptor type 1 , 1998, European journal of immunology.

[64]  D. Faustman,et al.  Islet Regeneration During the Reversal of Autoimmune Diabetes in NOD Mice , 2003, Science.

[65]  Bhagirath Singh,et al.  In vivo apoptosis of diabetogenic T cells in NOD mice by IFN-γ/TNF-α , 2004 .

[66]  P. Kloetzel,et al.  Immunoproteasome subunit LMP2 expression is deregulated in Sjögren’s syndrome but not in other autoimmune disorders , 2006, Annals of the rheumatic diseases.

[67]  Y. Fu,et al.  Reduced expression of Tap1 and Lmp2 antigen-processing genes in the nonobese diabetic (NOD) mouse due to a mutation in their shared bidirectional promoter. , 1997, Journal of immunology.

[68]  H. Ding,et al.  Relationship of large multifunctional proteasome 7 gene polymorphism with susceptibility to type 1 diabetes mellitus and DR3 gene. , 2001, Chinese medical journal.

[69]  Rena Li,et al.  Inhibition of p75 Tumor Necrosis Factor Receptor by Antisense Oligonucleotides Increases Hypoxic Injury and β-Amyloid Toxicity in Human Neuronal Cell Line* , 1997, The Journal of Biological Chemistry.

[70]  F. Breedveld,et al.  The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. , 2006, Arthritis and rheumatism.

[71]  W. Hagopian,et al.  Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years. , 2009, Clinical immunology.

[72]  E. Fonseca,et al.  Psoriasiform Eruption Induced by Infliximab , 2004, The Annals of pharmacotherapy.

[73]  M. Lenardo.  Interleukin-2 programs mouse alpha beta T lymphocytes for apoptosis. , 1991, Nature.

[74]  G. Tsokos,et al.  Abnormal T lymphocyte signal transduction in systemic lupus erythematosus. , 2002, Current directions in autoimmunity.

[75]  B. Seed,et al.  Regulated commitment of TNF receptor signaling: a molecular switch for death or activation. , 1999, Immunity.

[76]  N. Taylor,et al.  Tumor Necrosis Factor Promotes Human T‐Cell Development in Nonobese Diabetic/Severe Combined Immunodeficient Mice , 2004, Stem Cells.

[77]  H. Inoko,et al.  Polymorphisms in TNFA and TNFR2 affect outcome of unrelated bone marrow transplantation , 2002, Bone Marrow Transplantation.

[78]  D. Goeddel,et al.  A novel family of putative signal transducers associated with the cytoplasmic domain of the 75 kDa tumor necrosis factor receptor , 1994, Cell.

[79]  Tomohiro Watanabe,et al.  NOD2 is a negative regulator of Toll-like receptor 2–mediated T helper type 1 responses , 2004, Nature Immunology.

[80]  Vishva Dixit,et al.  Death receptor signal transducers: nodes of coordination in immune signaling networks , 2009, Nature Immunology.

[81]  A. Hoffmann,et al.  Circuitry of nuclear factor kappaB signaling. , 2006, Immunological reviews.

[82]  J. Gaglia,et al.  Islet Recovery and Reversal of Murine Type 1 Diabetes in the Absence of Any Infused Spleen Cell Contribution , 2006, Science.

[83]  K. Kretschmer,et al.  Making regulatory T cells with defined antigen specificity: role in autoimmunity and cancer , 2006, Immunological reviews.

[84]  B. Prum,et al.  Association between tumor necrosis factor receptor II and familial, but not sporadic, rheumatoid arthritis: evidence for genetic heterogeneity. , 2002, Arthritis and rheumatism.

[85]  K. Herold,et al.  Generation and function of human regulatory CD8+ T cells induced by a humanized OKT3 monoclonal antibody hOKT3gamma1 (Ala-Ala). , 2008, Human immunology.

[86]  M. Feldmann,et al.  Role of cytokines in rheumatoid arthritis. , 1996, Annual review of immunology.

[87]  Y. Fu,et al.  Linkage of faulty major histocompatibility complex class I to autoimmune diabetes. , 1991, Science.

[88]  Dae Kim,et al.  AIMP2 promotes TNFα-dependent apoptosis via ubiquitin-mediated degradation of TRAF2 , 2009, Journal of Cell Science.

[89]  C. Janeway,et al.  Identification of an MHC class I-restricted autoantigen in type 1 diabetes by screening an organ-specific cDNA library , 1999, Nature Medicine.

[90]  I. Rosner,et al.  Increased CD8+ T Cell Apoptosis in Scleroderma Is Associated with Low Levels of NF-κB , 2004, Journal of Clinical Immunology.

[91]  S. Macura,et al.  Tumor Necrosis Factor α is Reparative via TNFR1 in the Hippocampus and via TNFR2 in the Striatum after Virus‐Induced Encephalitis , 2009, Brain pathology.

[92]  M. Slevin,et al.  Infusion of tumor necrosis factor (TNF) causes an increase in circulating TNF-binding protein in humans. , 1990, Cytokine.

[93]  C. Janeway,et al.  Local expression of transgene encoded TNF alpha in islets prevents autoimmune diabetes in nonobese diabetic (NOD) mice by preventing the development of auto-reactive islet-specific T cells , 1996, The Journal of experimental medicine.

[94]  K. Tokunaga,et al.  Association of tumor necrosis factor receptor 2 (TNFR2) polymorphism with susceptibility to systemic lupus erythematosus. , 1999, Tissue antigens.

[95]  U. Chaudhari,et al.  Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial , 2001, The Lancet.

[96]  J. Killestein.  Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. , 2002, The New England journal of medicine.

[97]  K. Van Steen,et al.  Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study. , 2003, Gastroenterology.

[98]  G. Kollias,et al.  Tumor Necrosis Factor (TNF) Receptor Shedding Controls Thresholds of Innate Immune Activation That Balance Opposing TNF Functions in Infectious and Inflammatory Diseases , 2004, The Journal of experimental medicine.

[99]  P. Scheurich,et al.  TNFR80-dependent enhancement of TNFR60-induced cell death is mediated by TNFR-associated factor 2 and is specific for TNFR60. , 1998, Journal of immunology.

[100]  J. Satoh,et al.  Recombinant human tumor necrosis factor alpha suppresses autoimmune diabetes in nonobese diabetic mice. , 1989, The Journal of clinical investigation.

[101]  V. D’Agati,et al.  Development of glomerulonephritis during anti-TNF-alpha therapy for rheumatoid arthritis. , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[102]  George Kollias,et al.  A Critical Role of the p75 Tumor Necrosis Factor Receptor (p75TNF-R) in Organ Inflammation Independent of  TNF, Lymphotoxin α, or the p55TNF-R , 1998, The Journal of experimental medicine.

[103]  D. Männel,et al.  Cutting Edge: Expression of TNFR2 Defines a Maximally Suppressive Subset of Mouse CD4+CD25+FoxP3+ T Regulatory Cells: Applicability to Tumor-Infiltrating T Regulatory Cells1 , 2008, The Journal of Immunology.

[104]  E. Leshinsky‐Silver,et al.  TNF Promoter Polymorphisms and Modulation of Growth Retardation and Disease Severity in Pediatric Crohn's Disease , 2005, The American Journal of Gastroenterology.

[105]  T. Hayashi,et al.  Selected contribution: Association of gender-related LMP2 inactivation with autoimmune pathogenesis. , 2001, Journal of applied physiology.

[106]  I. Georgiou,et al.  The role of tumor necrosis factor (TNF)-alpha and TNF receptor polymorphisms in susceptibility to ankylosing spondylitis. , 2009, Clinical and experimental rheumatology.

[107]  F. Balkwill.  Tumour necrosis factor and cancer , 2009, Nature Reviews Cancer.

[108]  M. Lenardo,et al.  Requirement for TNF-alpha and IL-1 alpha in fetal thymocyte commitment and differentiation. , 1995, Science.

[109]  L. Cantley,et al.  The Crohn's Disease Protein, NOD2, Requires RIP2 in Order to Induce Ubiquitinylation of a Novel Site on NEMO , 2004, Current Biology.

[110]  J. Vauthey,et al.  A human tumor necrosis factor p75 receptor agonist stimulates in vitro T cell proliferation but does not produce inflammation or shock in the baboon , 1996, The Journal of experimental medicine.

[111]  R. Offringa,et al.  C3-symmetric peptide scaffolds are functional mimetics of trimeric CD40L , 2005, Nature chemical biology.

[112]  A. Klinkhoff.  Biological agents for rheumatoid arthritis: targeting both physical function and structural damage. , 2004, Drugs.

[113]  K. Sunagawa,et al.  Tumor necrosis factor-alpha is toxic via receptor 1 and protective via receptor 2 in a murine model of myocardial infarction. , 2007, American journal of physiology. Heart and circulatory physiology.

[114]  J. Tschopp,et al.  The RIP kinases: crucial integrators of cellular stress. , 2005, Trends in biochemical sciences.

[115]  R. Gentz,et al.  Two human TNF receptors have similar extracellular, but distinct intracellular, domain sequences. , 1990, Cytokine.

[116]  G. Tilz,et al.  Soluble receptors for tumour necrosis factor in clinical laboratory diagnosis , 1995, European journal of haematology.

[117]  Crystallization and preliminary X-ray analysis of the tumour necrosis factor alpha-tumour necrosis factor receptor type 2 complex. , 2009, Acta crystallographica. Section F, Structural biology and crystallization communications.

[118]  Rena Li,et al.  Target Depletion of Distinct Tumor Necrosis Factor Receptor Subtypes Reveals Hippocampal Neuron Death and Survival through Different Signal Transduction Pathways , 2002, The Journal of Neuroscience.

[119]  S. Deventer,et al.  Inhibition of the release of soluble tumor necrosis factor receptors in experimental endotoxemia by an anti-tumor necrosis factor-α antibody , 2005, Journal of Clinical Immunology.

[120]  D. Faustman,et al.  The primacy of CD8 T lymphocytes in type 1 diabetes and implications for therapies , 2009, Journal of Molecular Medicine.

[121]  Ingela Parmryd,et al.  Apoptotic crosstalk of TNF receptors: TNF-R2-induces depletion of TRAF2 and IAP proteins and accelerates TNF-R1-dependent activation of caspase-8. , 2002, Journal of cell science.

[122]  A. Bollon,et al.  Tumor necrosis factor activities and cancer therapy--a perspective. , 1993, Pharmacology & therapeutics.

[123]  F. Spinella,et al.  Expression of the p75 TNF Receptor Is Linked to TNF-Induced NFκB Translocation and Oxyradical Neutralization in Glial Cells , 2002, Neurochemical Research.

[124]  N. Amariglio,et al.  TNF Activates a NF-κB–Regulated Cellular Program in Human CD45RA– Regulatory T Cells that Modulates Their Suppressive Function , 2010, The Journal of Immunology.

[125]  Michael Karin,et al.  Nod2 Mutation in Crohn's Disease Potentiates NF-κB Activity and IL-1ß Processing , 2005, Science.

[126]  L. Tartaglia,et al.  A novel domain within the 55 kd TNF receptor signals cell death , 1993, Cell.

[127]  J. Drijfhout,et al.  Autoreactive CD8 T cells associated with β cell destruction in type 1 diabetes , 2005 .

[128]  S. Böhringer,et al.  Inhibitors in the NFκB cascade comprise prime candidate genes predisposing to multiple sclerosis, especially in selected combinations , 2002, Genes and Immunity.

[129]  L. Cardon,et al.  Inflammatory bowel disease is associated with a TNF polymorphism that affects an interaction between the OCT1 and NF(-kappa)B transcription factors. , 2002 .

[130]  Jun Wang,et al.  Small-Molecule Inhibition of TNF-α , 2005, Science.

[131]  Peter Scheurich,et al.  Control of Receptor-induced Signaling Complex Formation by the Kinetics of Ligand/Receptor Interaction* , 2002, The Journal of Biological Chemistry.

[132]  D. Docheva,et al.  IKK-2 is required for TNF-α-induced invasion and proliferation of human mesenchymal stem cells , 2008, Journal of Molecular Medicine.

[133]  Meijing Wang,et al.  Mechanisms of Sex Differences in TNFR2-Mediated Cardioprotection , 2008, Circulation.

[134]  W. Fiers,et al.  Cytotoxicity in L929 murine fibrosarcoma cells after triggering of transfected human p75 tumour necrosis factor (TNF) receptor is mediated by endogenous murine TNF. , 1995, Cytokine.

[135]  K. Tamura,et al.  Polymorphisms of the TNF gene and the TNF receptor superfamily member 1B gene are associated with susceptibility to ulcerative colitis and Crohn's disease, respectively , 2002, Immunogenetics.

[136]  Yili Yang,et al.  TNF-RII and c-IAP1 mediate ubiquitination and degradation of TRAF2 , 2002, Nature.

[137]  P. Rutgeerts,et al.  Tumour necrosis factor‐α receptor 1 and 2 polymorphisms in inflammatory bowel disease and their association with response to infliximab , 2004, Alimentary pharmacology & therapeutics.

[138]  R L Kassel,et al.  An endotoxin-induced serum factor that causes necrosis of tumors. , 1975, Proceedings of the National Academy of Sciences of the United States of America.

[139]  D. Faustman,et al.  The therapeutic potential of tumor necrosis factor for autoimmune disease: a mechanistically based hypothesis , 2005, Cellular and Molecular Life Sciences CMLS.

[140]  S. Yarkoni,et al.  Mechanisms of T regulatory cell function. , 2008, Autoimmunity reviews.

[141]  D. Goeddel,et al.  The TNF receptor 1-associated protein TRADD signals cell death and NF-κB activation , 1995, Cell.

[142]  L. Tartaglia,et al.  The two different receptors for tumor necrosis factor mediate distinct cellular responses. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[143]  H. Holtmann,et al.  Antibodies to a soluble form of a tumor necrosis factor (TNF) receptor have TNF-like activity. , 1990, The Journal of biological chemistry.

[144]  D. Faustman,et al.  Antigen Processing and Autoimmunity: Evaluation of mRNA Abundance and Function of HLA‐linked Genes a , 1998, Annals of the New York Academy of Sciences.

[145]  George Kollias,et al.  The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor , 1995, Cell.

[146]  L. Klareskog,et al.  Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial , 2004, The Lancet.

[147]  M. Lenardo,et al.  Induction of apoptosis in mature T cells by tumour necrosis factor , 1995, Nature.

[148]  V. D’Agati,et al.  Development of glomerulonephritis during anti-TNF-α therapy for rheumatoid arthritis , 2005 .

[149]  Schumacher Hr,et al.  Leukocytoclastic vasculitis due to etanercept. , 2000 .

[150]  T. Laessig,et al.  Suppression of Death Receptor Signaling in Cerebellar Purkinje Neurons Protects Neighboring Granule Neurons from Apoptosis via an Insulin-like Growth Factor I-dependent Mechanism* , 2002, The Journal of Biological Chemistry.

[151]  J. Stroehlein,et al.  Pustular psoriasis induced by infliximab. , 2004, Journal of drugs in dermatology : JDD.

[152]  J. Guilhou,et al.  Psoriatic lesions induced by antitumour necrosis factor‐α treatment: two cases , 2004, The British journal of dermatology.